Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Afric

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

The latest Pulmonary Arterial Hypertension Market report from Fairfield Market Research reveals global sales reached US$7.9 billion in 2024. Projected to grow at a rate of 8% from 2024 to 2031, the market is expected to reach US$13.2 billion by 2031. The Prostacyclin and Prostacyclin Analogs segment is expected to exhibit the highest revenue growth rate during the period from 2024 to 2031.

The market is expected to experience significant growth in the endothelin receptor antagonist segment from 2024 to 2031. These antagonists are commonly prescribed to address various aspects of pulmonary arterial hypertension (PAH), including heart and lung damage, slowing down PAH progression, and dilating blood vessels.

Clinical studies have demonstrated that individuals with pulmonary arterial hypertension tend to produce excessive endothelin, contributing to hypertension. Consequently, doctors often recommend endothelin receptor antagonists to reduce endothelin levels in the blood vessels. Furthermore, the growing interest in research and development related to endothelin receptor antagonists is expected to further fuel the segment's growth. Research has also highlighted additional therapeutic benefits associated with targeting the endothelin receptor, particularly in the context of pulmonary arterial hypertension treatment.

Insights on Prostacyclin and Prostacyclin Analogs

The Prostacyclin and Prostacyclin Analogs segment are anticipated to exhibit the highest CAGR rate from 2024 to 2031. It is estimated that new cases of pulmonary hypertension occur in one to two individuals per million in the United States annually, according to the National Organization for Rare Disorders. A similar rate is expected in Europe. Pulmonary hypertension can affect individuals of all ages and becomes more common as they age. The rapid increase in its prevalence is attributed to lifestyle changes, including reduced physical activity and increased consumption of alcohol and tobacco, both of which elevate the risk of hypertension and high blood pressure.

Market Dominance of Oral Route of Administration

The Oral Route of Administration accounted for approximately 60% of the pulmonary arterial hypertension market share in 2024. Oral medications for PAH treatment include Letairis, Opsumit, Adcirca, and Revatio. Several factors contribute to the preference for oral drug administration, including patient safety, high effectiveness, and rapid drug delivery.

Region-wise Insights

North America, particularly the United States, is poised to provide the most substantial opportunity in the Pulmonary Arterial Hypertension market. The dominant position is attributed to the well-established healthcare infrastructure, facilitating access to advanced treatments. Factors such as increased awareness, efficient diagnosis rates, and robust government support contribute significantly to market growth. The region benefits from the presence of major competitors and a well-structured reimbursement system, further fueling the demand for advanced medical services in Pulmonary Arterial Hypertension.

Country-wise Insights

U.S. Market Analysis

The United States is expected to hold the largest market share by the end of 2031, significantly contributing to market growth. Pulmonary Arterial Hypertension (PAH) is considered a rare condition in the U.S., with a yearly diagnosis of around 500 – 1,000 new cases. The utilization of PAH extends beyond its traditional applications, encompassing various fields such as vaccine administration, hormonal delivery, cancer therapy, and pain management, which fuels market expansion in the United States.

U.K. Market Analysis

In the United Kingdom, idiopathic pulmonary arterial hypertension affects a substantial population of individuals. Consequently, the country's market is expected to achieve a valuation of considerable value by 2031. The growth trajectory is predicted to be stable, with a consistent CAGR from 2024 to 2031.

Japan Market Analysis

Japan has reported an estimated prevalence rate of pulmonary arterial hypertension at 3.2 cases per 100,000 individuals, with an annual incidence ranging from 70 to 100 cases. Despite these statistics, substantial investments have been directed towards the prevention and management of pulmonary arterial hypertension, contributing to the market's substantial value, as observed in 2021.

South Korea Market Analysis

South Korea demonstrates a consistent and steady market performance for pulmonary arterial hypertension. Statistical data indicates the diagnosis of over 1,307 patients between 2008 and 2016, resulting in an annual incidence rate of 4.84 patients per million individuals. As of 2021, the market in South Korea exhibited a reliable performance and was valued significantly.

Key Companies Profiled
• United Therapeutics Corporation
• Bayer
• Johnson & Johnson
• Novartis
• Lupin Pharmaceuticals
• Viatris Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd.

Market Segments Covered in Pulmonary Arterial Hypertension Market Analysis

By Drug Class
• Endothelin Receptor Antagonists
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

By Type
• Branded
• Generics

By Route of Administration
• Oral
• Intravenous/ Subcutaneous
• Inhalational

By Region
• North America
• Latin America
• Europe
• APAC
• MEA

Please note: The PDF e-mail from publisher version of this report is for a global site license. Delivery Timelines - 5 working days.